Ion Beam Applications SA IBA (GB:0GZK) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PanTera, a joint venture of IBA (Ion Beam Applications S.A), has raised EUR 93 million in an oversubscribed Series A funding round, led by EQT Life Sciences, to accelerate the production of actinium-225, a critical component for new targeted cancer treatments. The financing, which is the largest Series A in Belgium’s life sciences sector, brings the total raised to EUR 134 million and will support the construction of a new production facility. With IBA’s participation reducing to 31.3%, the transaction will positively impact IBA’s profits by approximately EUR 23 million over the next three years.
For further insights into GB:0GZK stock, check out TipRanks’ Stock Analysis page.